Avant Genomics Secures $3M+ to Automate Critical Step in Cancer Detection

CHARLOTTESVILLE, VA – May 13, 2026 – Avant Genomics, a biotech firm spun out of the University of Virginia, announced today it has successfully closed a funding round of more than $3 million. The capital is earmarked to accelerate the development of its Avant Source™ platform, a first-in-kind system designed to fully automate the sample preparation phase of liquid biopsies, a crucial tool in modern cancer care.

The investment round drew a diverse coalition of backers, including TitletownTech, Halyard Ventures, Virginia Venture Partners, CAV Angels, and the Global Impact Fund, signaling strong confidence in the company's mission to standardize a critical yet often overlooked step in precision oncology. The new funds will fuel continued research and development, scale up manufacturing, and expand the company's team of experts.

The Unsung Problem in Precision Oncology

The field of liquid biopsy—a simple blood test used to detect cancer signals—is transforming oncology. With a global market valued at nearly $11 billion in 2023 and projected to quadruple by 2030, these tests offer a less invasive alternative to tissue biopsies for early detection, treatment monitoring, and identifying patient-specific therapies. However, the promise of this technology hinges on the quality of its foundational step: preparing the sample.

Currently, the process of extracting the minuscule fragments of circulating tumor DNA (ctDNA) from a patient's blood is largely a manual craft. It involves dozens of intricate steps, making it time-intensive, costly, and highly susceptible to variability between technicians and laboratories. This inconsistency at the very beginning of the workflow can lead to reduced recovery of precious ctDNA, compromising the reliability of the final diagnostic result and creating a significant bottleneck that limits the technology's widespread clinical use.

“We believe precision cancer care starts with preparation, and this support helps accelerate that shift,” said Rachelle Turiello, PhD, CEO of Avant Genomics, in a statement. “Liquid biopsy is only as reliable as its sample preparation. We’re building a platform that standardizes the preparation workflow so results are consistent and scalable, unlocking broader use in clinical settings.”

Automation as the Answer: The Avant Source™ Platform

Avant Genomics aims to replace this manual variability with robotic precision. The company’s Avant Source™ platform is a fully integrated system engineered to automate the entire sample preparation workflow. According to the company, the platform dramatically reduces manual handling from over 50 steps down to just two, a key intervention designed to minimize the risk of human error and contamination.

The performance improvements claimed are substantial. Avant Genomics reports that its system can increase the yield of tumor-derived DNA by as much as 70% compared to existing semi-automated tools, while simultaneously cutting the total processing time in half. By removing the "noise" and inconsistency at the front end, the platform aims to deliver a purer, more concentrated sample for downstream analysis, thereby enhancing the sensitivity and reliability of the entire liquid biopsy test. This leap in efficiency and consistency could be pivotal in making advanced cancer diagnostics a routine part of patient care.

The technology is rooted in the founders' deep expertise in microfluidics and nucleic acid detection, allowing for precise manipulation of small fluid volumes to maximize the capture of target DNA molecules while minimizing loss.

A Confluence of Capital and Confidence

The over $3 million funding round is a strong vote of confidence from a diverse group of investors who see the strategic value in solving this foundational problem in diagnostics.

“We invested in Avant because the future of diagnostics and personalized medicine depends on automation,” noted Jill Enos, Managing Partner at TitletownTech, the venture capital firm formed by the Green Bay Packers and Microsoft. “As technology advances, what labs are capable of is moving faster than the workflows supporting them. Avant is helping close that gap by bringing consistency and scalability to a step that has historically limited the field.”

The investment also highlights a growing trend of fostering innovation within regional biotech hubs. Virginia Venture Partners, an equity program of the Virginia Innovation Partnership Corp. (VIPC), focuses on backing high-growth companies within the Commonwealth. “Avant Genomics is exactly the kind of company Virginia Venture Partners was designed to back,” said Alex Euler, Senior Investment Director. “With a world-class technical team, deep roots in the Virginia research ecosystem, and a platform that addresses a real and urgent unmet need... we’re proud to support the team and their journey.”

Support from CAV Angels, an investor group connected to the University of Virginia, further underscores the strong belief in the company’s potential, nurtured from its academic origins.

Navigating a Competitive and Regulated Landscape

Avant Genomics enters a competitive space dominated by established life sciences giants like QIAGEN, Thermo Fisher Scientific, and Promega, all of which offer their own semi-automated systems and kits for cfDNA extraction. These companies have extensive distribution networks and long-standing relationships with diagnostic labs worldwide.

To carve out its market share, Avant will need to prove its performance claims in real-world clinical settings and demonstrate a clear return on investment for labs grappling with increasing sample volumes. The company's focus on a fully integrated, "walk-away" system, as opposed to a collection of separate instruments and reagents, may serve as a key differentiator.

Beyond market competition, the company faces a rigorous regulatory journey. Any instrument intended for clinical diagnostic use in the United States must navigate the Food and Drug Administration (FDA) approval process. Depending on its intended use claims, the Avant Source™ platform could be classified as a Class I or II medical device, requiring a 510(k) submission to prove it is substantially equivalent to an existing product. A more stringent Premarket Approval (PMA) could be required if it is tied to a specific high-risk diagnostic test. Securing regulatory clearance is a critical, and often lengthy, step toward commercialization and widespread clinical adoption.

From University Lab to Commercial Vanguard

Avant Genomics stands as a testament to the power of translating academic research into commercial innovation. The female-founded company was established by CEO Rachelle Turiello, PhD, and COO Renna Nouwairi, PhD, who built the company upon their work in microfluidics at the University of Virginia. The firm holds exclusive intellectual property developed at the university, providing it with a strong technological foundation.

This recent funding is the latest in a series of accolades for the Charlottesville-based startup. The company has previously received early support through a National Science Foundation (NSF) SBIR Phase I grant, was named "Innovator of the Year" by the Charlottesville Business Innovation Council, and was selected as a 2025 Startup World Cup Regional Finalist. With fresh capital and a clear mission, Avant Genomics is now poised to move from development to commercialization, aiming to set a new standard for reliability in the rapidly evolving world of cancer diagnostics.